HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Cali Biosciences / Equity Capital Markets

<ul>
<li>Both the postoperative pain management and the expansive application of anesthetics in various fields would increase the market demand for ropivacaine.</li>
<li>
<a href="https://www.smartkarma.com/entities/cali-biosciences-co-ltd" target="_blank" data-smartkarma-citation="entities:35539:1" rel="noopener">Cali Biosciences (CALI HK)</a>’s core product, the ropivacaine long-acting analgesic injection drug candidate CPL-01, would have to face the challenges of fierce competition, uncertain market acceptance, and negative policy impact.</li>
<li>Together with other concerns such as slow development progress, “not rich enough” pipeline and potential liquidity risk, we are conservative about Cali’s outlook at the current stage.  </li>
</ul>


Both the postoperative pain management and the expansive application of anesthetics in various fields would increase the market demand for ropivacaine.

Cali Biosciences (CALI HK)’s core product, the ropivacaine long-acting analgesic injection drug candidate CPL-01, would have to face the challenges of fierce competition, uncertain market acceptance, and negative policy impact.
Together with other concerns such as slow development progress, “not rich enough” pipeline and potential liquidity risk, we are conservative about Cali’s outlook at the current stage.  


Pre-IPO Cali Biosciences - The Industry, the Business and the Concerns

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Cali Biosciences - The Industry, the Business and the Concerns

Cali’s core product will face fierce competition,uncertain market acceptance and negative policy impact. The pipeline isn't rich with slow...

Xinyao (Criss) Wang